AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

EIKN · NASDAQ · Biotechnology

Eikon Therapeutics (EIKN)

Develops oncology therapies using live-cell single-molecule tracking and in-licensed clinical assets.

$11.38

At close+0.50 (+4.60%)

Watchlist

In millions of USD, except per-share figures

In millions	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Cost of revenue	5	5	5
Gross profit	−5	−5	−5
	78	82	88
Research & development	65	70	75
	18	12	13
General & administrative	18	0	0
Other expenses	−5	0	0
Operating income	−83	−87	−93
	4	4	5
Interest income	3	4	5
Other non-operating income	−4	−4	0
Income before tax	−80	−83	−88
Net income from continuing operations	−80	−83	−88
Net income	−80	−83	−88
EPS, basic	−$1.47	−$1.53	−$1.63
EPS, diluted	−$1.47	−$1.53	−$1.63
Weighted average shares, basic	54	54	54
Weighted average shares, diluted	54	54	54
EBITDA	−75	−78	−88
Depreciation & amortization	5	5	5
EBIT	−80	−83	−93